Navigation Links
US WorldMeds Announces the Launch of Revonto™ (dantrolene sodium for injection)
Date:7/6/2010

LOUISVILLE, Ky., July 6 /PRNewswire/ -- US WorldMeds is proud to announce the launch of Revonto™ (dantrolene sodium for injection), the first patented scientific advancement in the treatment of malignant hyperthermia (MH).  The time to reconstitute dantrolene sodium for injection has been dramatically reduced to approximately 20 seconds or until the solution is clear.  Revonto™ retains the cost-savings of the original dantrolene sodium for injection product while offering a significant improvement in pharmacotherapy.

"The enhanced reconstitution time is an important and critical scientific improvement to intravenous dantrolene sodium, the only available antidote for the treatment of malignant hyperthermia.  MH is triggered in some patients by certain inhalation anesthetics during surgery.  A rapid response to MH onset is critical because temperatures exceeding 105F degrees and death due to this condition can occur as early as 30 minutes from onset." says Dr. George A. Digenis, Chief Scientific Officer of US WorldMeds.

Fatal and non-fatal liver disorders of an idiosyncratic or hypersensitivity type may occur with dantrolene sodium therapy.  There have been reports of thrombophlebitis following administration of intravenous dantrolene.  There have been rare reports of urticaria and erythema possibly associated with the administration of i.v. dantrolene sodium. For additional information, including the full prescribing information for Revonto™, please visit US WorldMeds' website at www.revonto.com.

For more information on malignant hyperthermia, please visit The Malignant Hyperthermia Association of the United States (MHAUS) website at www.mhaus.org

Revonto™ will be available on GPO contracts as a dropship via your wholesaler/distributor.

For Ordering Information Call: 1.877.411.USWM(8796).

About US WorldMeds

US WorldMeds, LLC, a specialty pharmaceutical company located in Louisville, Kentucky, is committed to developing, licensing, and marketing unique and significant pharmaceuticals that address unmet medical needs. US WorldMeds is committed to using science to make lives better. For more information, please visit www.usworldmeds.com


'/>"/>
SOURCE US WorldMeds
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bionovo Announces a $15 Million At-The-Market Firm Commitment Financing Agreement
2. Zimmer Holdings Announces Live Audio Webcast and Conference Call of Second Quarter 2010 Results
3. Fougera® Announces First Generic Approval of Adapalene Cream 0.1% (Rx), Equivalent to Differin®
4. Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
5. PolyTouch Medical Ltd. Announces the Appointment of Robert D. Fanelli, MD, FACS, FASGE as Medical Advisor
6. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
7. ProUroCare Medical Announces Offering of Replacement Warrants in Exchange for Early Exercise of Outstanding Warrants
8. MiMedx Group, Inc. Announces Release Date for Second Quarter Results
9. Aeras Global TB Vaccine Foundation Announces Appointment of Accomplished Pharmaceutical Executive as President and CEO
10. Jiangbo Pharmaceuticals Announces the Appointment of New Chief Executive Officer
11. Sysmex America Announces Executive Leadership Changes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... March 28, 2017  Medeon Biodesign, Inc., a ... is pleased to announce that the Company led ... Panther Orthopedics, Inc., a San Jose, ... solutions for orthopedic extremity applications.  ... rapidly, primarily due to procedure volume growth, lifestyle ...
(Date:3/27/2017)... TEL-AVIV, Israel , March 27, 2017 /PRNewswire/ ... TASE: THXBY), a specialty clinical-stage pharmaceutical company specializing in the ... of its public offering in the ... Shares (ADSs), each ADS representing 40 ordinary shares ... per ADS. In addition, Therapix has granted the ...
(Date:3/27/2017)... STUTTGART, Germany , March 27, 2017 /PRNewswire/ ... provide over 7,000 attendees and more than 600 ... learn, and discover opportunities and solutions that will ... - 6 April 2017 at the Messe Stuttgart, ... is the preeminent medical technology platform showcasing the ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... March 28, 2017 , ... Calibration, qualification, ... ensuring high-quality results and maintaining GMP and USP compliance. In a new webinar ... with GMP requirements " these requirements are explained. The challenge is to ...
(Date:3/28/2017)... ... 28, 2017 , ... Neurotechnology , a provider of ... attendance tracking products: the new NCheck Cloud Bio Attendance cloud-based service and the ... face recognition to enable users to check in and out from anywhere via ...
(Date:3/28/2017)... Appleton, WI (PRWEB) , ... March 28, 2017 ... ... how self-funded health plans work, the Self-Funding Success website has recently developed and ... about Self-Funded Health Plans ” was created based on common inquiries the site’s ...
(Date:3/28/2017)... ... , ... A minimally invasive porcelain veneer is increasing in ... of Dental Laboratories (NADL) is informing dentists about the benefits of minimally invasive ... laboratories and technicians that create these veneers. , According to National Board ...
(Date:3/28/2017)... (PRWEB) , ... March 28, 2017 , ... Public relations ... and across a variety of business channels. , While many results are clear, much ... public relations program. , When it comes to measurement, firms should always take ...
Breaking Medicine News(10 mins):